If you live with PTSD, or love someone who does, you've probably seen the headlines. Veterans describing the storm finally lifting. Trials with remission rates that sound almost too good. And maybe a quiet question underneath: could this be what finally helps?
It might be, for some people. But the honest answer is more careful than the headlines, and the details matter a lot. Here's where the science stands in late 2026.
Why PTSD is so hard to treat
PTSD can lock the nervous system into survival mode: nightmares, hypervigilance, flashbacks, numbness, a body that won't stand down. Proven therapies like Cognitive Processing Therapy, Prolonged Exposure and EMDR help many people. But they ask you to revisit the worst moments of your life, and many people can't tolerate that, or drop out. For more than two decades, only two medications, sertraline and paroxetine, have been FDA-approved for PTSD.
How psychedelics might help
Researchers think certain psychedelics may work less as a pill that fixes PTSD and more as a catalyst that makes therapy possible. Under the right conditions, they may:
Lower fear and defensiveness enough to approach traumatic memories without being overwhelmed
Increase feelings of safety, trust and self-compassion
Open a window of greater mental flexibility, where old patterns can shift
The key word is assisted. In every promising study, the drug was paired with many hours of preparation and integration therapy with trained clinicians.
MDMA
MDMA has the deepest evidence base. Two Phase 3 trials, run by the company now called Resilient Pharmaceuticals (formerly Lykos Therapeutics and MAPS PBC), found MDMA plus therapy significantly reduced PTSD symptoms compared with placebo plus the same therapy (AJMC).
But in August 2024 the FDA declined to approve it. An advisory panel had raised concerns that participants could often tell whether they got MDMA, about how adverse events were recorded, and about how long benefits last (Clinical Trials Arena). In August 2026, the company quietly resubmitted its application, drawing on additional data including a VA study with long-term follow-up (Psychedelic Alpha). A decision could come in the coming months.
Psilocybin
In July 2026, Ohio State researchers published the first U.S. trial of psilocybin-assisted therapy in veterans with severe, treatment-resistant PTSD. Nine of 12 participants no longer met criteria for PTSD one month after treatment, with no serious adverse events and no increase in suicidal thinking (Ohio State News).
Two cautions the researchers themselves emphasize: it was a small trial with no control group, which tends to inflate results, and symptoms started dropping during the preparation therapy, before anyone took psilocybin. As one of the lead researchers put it, the drug opens a window; the healing happens in the therapy and the changes people make afterward.
Ibogaine
A 2024 Stanford study followed 30 special operations veterans with traumatic brain injuries who received ibogaine with magnesium at a monitored clinic in Mexico. One month later, PTSD symptoms had dropped by 88% on average (Stanford Medicine). Ibogaine also carries serious cardiac risk and is now the focus of federal and Texas-funded trials. (For the full picture, see our post on ibogaine.)
Ketamine
Ketamine is the one psychedelic-adjacent medicine legally available today, prescribed off-label in clinics. Some people with PTSD find relief, but the research for PTSD specifically is less settled than for depression, and it should be part of a broader treatment plan with a qualified provider.
Where things stand right now
None of these psychedelics is FDA-approved for PTSD yet. MDMA's resubmitted application is under review.
The federal government is leaning in. An April 2026 executive order directed agencies to accelerate psychedelic research. The VA is involved in about 20 active psychedelic clinical trials and has launched a placebo-controlled MDMA trial for veterans with PTSD and alcohol use disorder, while stressing that clinical use inside the VA will depend on FDA approval (MyChesCo).
Clinical trials are the legitimate way in today. If you're interested, ask your clinician or search ClinicalTrials.gov.
The risks, especially for trauma survivors
The same openness that makes these medicines promising also makes them risky for people carrying trauma.
Re-traumatization. Without skilled support, an experience can surface overwhelming memories with nowhere safe to put them.
Destabilization. Some people feel worse for a time afterward: more anxious, more raw, sleeping poorly. Trials include careful monitoring for exactly this reason.
Vulnerability to harm. People in altered states, especially trauma survivors, can be more suggestible and more trusting. There have been documented cases of facilitators, including in research settings, crossing serious boundaries. Underground settings carry far less accountability.
Physical risks. MDMA raises heart rate and blood pressure; ibogaine can cause dangerous heart rhythm problems.
Medication interactions. Antidepressants, mood stabilizers like lithium, and other medications common in PTSD treatment can interact dangerously or blunt effects. Never stop a prescribed medication on your own.
Who's usually excluded. Trials typically screen out people with psychotic disorders, bipolar disorder and certain heart conditions. Those exclusions exist for good reasons.
If you're considering it
Talk to a licensed trauma-informed clinician first. Ideally one who knows the psychedelic research and won't dismiss you or cheerlead.
Prefer clinical trials or legal, medically supervised settings over underground ones.
Ask hard questions about anyone offering psychedelic support: training, licensure, consent practices, what happens if you're in crisis, and how they handle touch. Vague answers are a red flag.
Don't go it alone. Have people around you who know what you're doing and can support you before and after.
Plan for the after. The weeks following an experience are often when the real work, and the real risk, shows up.
What integration coaching can and can't do
I want to be clear: I'm not a therapist, and integration coaching is not a treatment for PTSD. If you have PTSD, a licensed trauma therapist should be at the center of your care.
What I can offer is a complement to that care. I work with people before and after psychedelic experiences, whether in a trial, at a retreat or on their own, to help them prepare thoughtfully, make sense of what came up, and turn insight into everyday change. I often work alongside clients' therapists. I also teach consent in psychedelic spaces, and I'm glad to help you think through whether a setting or facilitator seems safe.
That's the work I do with individuals and couples, drawing on my background teaching consent in psychedelic spaces. I don't provide or source substances, and I won't tell you whether to use them. I'll help you make sense of what you experienced and build on it.
Sessions are in person in Brooklyn or online anywhere in New York. Reach out through the contact form.
Interested in transforming your life? Reach out today.
Sign up for our newsletter for occasional reflections, events, and offerings from Brooklyn Balance. No spam — just thoughtful updates.
Josh Jupiter is a psychedelic integration coach and founder of Brooklyn Balance, a wellness practice in Brooklyn, New York. This article is for educational and informational purposes only and does not constitute medical or legal advice. For guidance on any of the therapeutic options discussed, please consult a qualified healthcare provider. For information on clinical trials, visit ClinicalTrials.gov.
Ready to go deeper? Reach out to Josh to learn about one-on-one integration coaching, group programs, and upcoming workshops at Brooklyn Balance.